HORMONARY REPLACEMENT THERAPY
AbstractMenopause is defined as permanent cessation ofmenstruation and the mean age of menopause inUnited States is 51 years, with a normal distributioncurve and 95% confidence limits between the ages of45 and 55 years. At this age only a few primordialfollicles are left and hence the production of estrogensby ovary is decreased. These small amounts ofestrogens cannot cause surge of LH and FSH essentialfor ovulation. When ovulation does not occur, corpusluteuin is not formed and there is no secretion ofestrogens and progesterone. Due to this weak, negativefeedback effect of estrogen and progesteroneproduction of LH and FSH increases and so regularcycles disappear. It is found that steroid hormones(estrogen and progesterone) are decreased andgonadotrophins (LH and FSH) are increased aftermenopause. These findings are important from thediagnostic point of view. These hormonal changesbegin about 5 years before the actual menopause.These changes lead to the symptoms like hot flushes,vaginal atrophy, depression, anxiety, memory loss andnervousness. Estrogen deficiency also results in anincreased risk of cardiovascular disease and anaccelerated loss of bone mass, causing an increasedrisk of fractures. The leading cause of death in womenis cardiovascular disease. Estrogen replacementtherapy relieves these symptoms and allows thepatients to sleep better.
Paganini-Hill A, Henderson VW. Estrogen deficiency
and risk of Alzheimer’s disease in women. Am J
Eidermoll 1994; 140:256-261.
Tang MX, Jacobs D, Steen Y, Marder K, Schofield P,
Gurland B et al. Effect of estrogen during menopause
on risk and age at onset of Alzheimer’s disease. Lancet
; 348: 429-432.
Daly E, Verry MP, Hawkins MM, Larson JL, Gough D,
Marsh S. Risk of venous thrombo embolism in users of
HRT. Lancet 1996; 348: 977-980.
Stampfer NJ, Willet WC, Colditz GA et al. A
prospective study of post-menopausal estrogen therapy
and coronary heart disease. N Engl J Med 1985; 313:
Lancaster T, Surmom G, Lawrance M et al. HRT
characteristics of users and non-users in a British
Journal Practice Cohort identified through
computerised prescribing records. J Epidemiol
Common Health 1995; 49: 389-394.
Wilson PWF, Garrison RJ, Black DM et al. Postmenopausal, estrogen use, cigarette smoking and
cardiovascular morbidity in women over 50. The
Framingham study. N Engl J Med 1985; 313: 1038-
Berrett Conner E, Wingard Dl, Crigni MH.
Postmenopausal estrogen use and heart disease risk
factors in the 1980’s. JAMA 1989; 261: 2095-2100.
The writing group for PEP1 trial. Effects of estrogen or
estrogen progesterone regimens on heart disease side
factors in post-menopausal women. JAMA 1995; 273:
Lobo RA. Effects of HRT on bids and lipoproteins in
post-menopausal women (Review). J Clin Endocrinol
Metab 1991; 73: 925-930.
Marjooni S, Dupont A, Labrie F et al. Changes in
plasma lipoproteins and apolipoprotein composition in
relation to oral versus transdermal administration of
estrogen alone or in cyclic association with utrogeston
in menopausal women. J Clin Endocrinol Metab 1991;
Lindoff C, Peterson F, Lecondee I, Martinsson G,
Astedl B. Transdermal estrogen replacement therapy.
Beneficial effects on hemostatic risk factors for CVD.
Maturition 1996; 24: 43-50.
Adami S, Suppi R, Bertoldo F et al. Transdermal
estrodiol in the treatment of post-menopausal bone loss.
Bone Miner 1989; 7: 79-86.
Errkola R, Holma P, Jarvi T et al. Transdermal estrogen
replacement therapy in Finnish population. Maturities
; 13: 275-281.
Frenkel Y, Mopermik G, Lazer S et al. Acceptability
and skin reactions to transdermal estrogen replacement
therapy, in relation to climate. Maturities 1994. 20: 31-
Granberg S. Sonography of endometrium in the postmenopausal women. Anna] Med. 1996; 26: 81-83.
Vtian WH. Transdermal estradiol overall safety profile.
Am J Obstet Gynecol 1987; 156: 1335-1338.
Wolff F. Estrogen substitution therapy in the
menopause comparison between a transdermal and an
oral application. Munchener, Medizinische
Wochenschriff 1988; 130: 60-65.